Yu Jieh-Juen, Goluguri Tatareddy, Guentzel M Neal, Chambers James P, Murthy Ashlesh K, Klose Karl E, Forsthuber Thomas G, Arulanandam Bernard P
South Texas Center for Emerging Infectious Diseases, One UTSA Circle, University of Texas at San Antonio, San Antonio, TX 78249, USA.
Clin Vaccine Immunol. 2010 Feb;17(2):215-22. doi: 10.1128/CVI.00361-09. Epub 2009 Dec 16.
There is no licensed vaccine against the intracellular pathogen Francisella tularensis. The use of conventional mouse strains to screen protective vaccine antigens may be problematic, given the differences in the major histocompatibility complex (MHC) binding properties between murine and human antigen-presenting cells. We used engineered humanized mice that lack endogenous MHC class II alleles but that express a human HLA allele (HLA-DR4 transgenic [tg] mice) to identify potential subunit vaccine candidates. Specifically, we applied a biochemical and immunological screening approach with bioinformatics to select putative F. tularensis subsp. novicida T-cell-reactive antigens using humanized HLA-DR4 tg mice. Cell wall- and membrane-associated proteins were extracted with Triton X-114 detergent and were separated by fractionation with a Rotofor apparatus and whole-gel elution. A series of proteins were identified from fractions that stimulated antigen-specific gamma interferon (IFN-gamma) production, and these were further downselected by the use of bioinformatics and HLA-DR4 binding algorithms. We further examined the validity of this combinatorial approach with one of the identified proteins, a 19-kDa Francisella tularensis outer membrane protein (designated Francisella outer membrane protein B [FopB]; FTN_0119). FopB was shown to be a T-cell antigen by a specific IFN-gamma recall assay with purified CD4(+) T cells from F. tularensis subsp. novicida DeltaiglC-primed HLA-DR4 tg mice and cells of a human B-cell line expressing HLA-DR4 (DRB1*0401) functioning as antigen-presenting cells. Intranasal immunization of HLA-DR4 tg mice with the single antigen FopB conferred significant protection against lethal pulmonary challenge with an F. tularensis subsp. holarctica live vaccine strain. These results demonstrate the value of combining functional biochemical and immunological screening with humanized HLA-DR4 tg mice to map HLA-DR4-restricted Francisella CD4(+) T-cell epitopes.
目前尚无针对细胞内病原体土拉弗朗西斯菌的许可疫苗。鉴于鼠类和人类抗原呈递细胞之间主要组织相容性复合体(MHC)结合特性存在差异,使用传统小鼠品系筛选保护性疫苗抗原可能存在问题。我们利用缺乏内源性MHC II类等位基因但表达人类HLA等位基因的工程化人源化小鼠(HLA - DR4转基因[tg]小鼠)来鉴定潜在的亚单位疫苗候选物。具体而言,我们采用生化和免疫筛选方法并结合生物信息学,使用人源化HLA - DR4 tg小鼠来选择推定的土拉弗朗西斯菌新凶手亚种T细胞反应性抗原。用Triton X - 114去污剂提取细胞壁和膜相关蛋白,通过Rotofor仪器分级分离并进行全凝胶洗脱。从刺激抗原特异性γ干扰素(IFN - γ)产生的级分中鉴定出一系列蛋白质,并通过生物信息学和HLA - DR4结合算法进一步筛选。我们进一步用其中一种鉴定出的蛋白质——一种19 kDa的土拉弗朗西斯菌外膜蛋白(命名为土拉弗朗西斯菌外膜蛋白B [FopB];FTN_0119)检验了这种组合方法的有效性。通过用来自新凶手亚种DeltaiglC预致敏的HLA - DR4 tg小鼠的纯化CD4(+) T细胞和表达HLA - DR4(DRB1*0401)的人B细胞系细胞作为抗原呈递细胞进行特异性IFN - γ回忆试验,证明FopB是一种T细胞抗原。用单一抗原FopB对HLA - DR4 tg小鼠进行鼻内免疫,可使其对土拉弗朗西斯菌全北区亚种活疫苗株的致死性肺部攻击产生显著保护作用。这些结果证明了将功能性生化和免疫筛选与人源化HLA - DR4 tg小鼠相结合以绘制HLA - DR4限制的土拉弗朗西斯菌CD4(+) T细胞表位的价值。